Effects of the Tat basic domain on human immunodeficiency virus type 1 transactivation, using chemically synthesized Tat protein and Tat peptides

J Virol. 1994 May;68(5):3343-53. doi: 10.1128/JVI.68.5.3343-3353.1994.

Abstract

To study the structure relationship of different Tat domains, the full-length Tat protein Tat1-86, the gene product of the first exon Tat1-72 which retains full activity of the protein, and a panel of shorter peptides mimicking different regions of the primary structure of the Tat protein were chemically synthesized by the solid-phase method, using an efficient protocol. Synthetic Tat1-86 and Tat1-72 transactivated beta-galactosidase activity in HeLa cells containing the lacZ gene under the control of the human immunodeficiency virus type 1 long terminal repeat. Analyses of the activity of Tat1-86 and Tat1-72 with the sulfhydryl of cysteine residues free or protected by the acetamidomethyl group showed that only the Tat fragments with deprotected cysteine residues retain transactivation ability. In contrast, peptide Tat1-48 was inactive, with cysteine residues either free or protected. Similarly, other shorter synthetic peptides covering the different Tat domains were inactive. Interestingly, when peptides Tat1-48 and Tat38-60 were used simultaneously, a significant transactivation was obtained. This result suggests that both peptide domains are implicated in transactivation, probably by acting at two different sites. This permits us to propose a fundamentally new step in the understanding of the molecular mechanism of Tat transactivation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Base Sequence
  • Cysteine / pharmacology
  • Gene Products, tat / chemical synthesis
  • Gene Products, tat / pharmacology*
  • HIV Long Terminal Repeat / genetics
  • HIV-1 / genetics*
  • HeLa Cells
  • Humans
  • Molecular Sequence Data
  • Peptide Fragments / chemical synthesis
  • Peptide Fragments / pharmacology*
  • Recombinant Fusion Proteins / biosynthesis
  • Structure-Activity Relationship
  • Sulfhydryl Compounds / pharmacology
  • Transcriptional Activation / drug effects*
  • beta-Galactosidase / biosynthesis
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • Gene Products, tat
  • Peptide Fragments
  • Recombinant Fusion Proteins
  • Sulfhydryl Compounds
  • tat Gene Products, Human Immunodeficiency Virus
  • beta-Galactosidase
  • Cysteine